These increased numbers of Th17 cells, along with increased levels of IL-17 and other proinflammatory cytokines, contribute to growth, drug resistance, and apoptosis inhibition in B-cell lymphoma cells, as well as suppression of immune responses. The gene discussed is IL17A; the disease is B-cell non-Hodgkin lymphoma.